2018
SURG-06. LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY
Kamath A, Tatter S, Fecci P, Chen C, Chiang V, Rao G, Mohammadi A, Judy K, Field M, Neimat J, Leuthardt E, Kim A. SURG-06. LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY. Neuro-Oncology 2018, 20: vi251-vi251. PMCID: PMC6216263, DOI: 10.1093/neuonc/noy148.1042.Peer-Reviewed Original ResearchLaser interstitial thermal therapyBrain metastasesProcedural dataDeath rateAblation coverageMedian overall survivalAcceptable safety profileSingle-center experienceDay of procedureKaplan-Meier survivalNeurological tissuesAverage lesion volumeLocation of lesionsPreliminary outcomesInterstitial thermal therapyAdverse eventsOngoing registryOverall survivalCenter experienceSafety profileMean ageInvasive optionTarget lesionsProcedural efficacyLesion volume
2016
Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery
Qian JM, Yu JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 2016, 122: 3051-3058. PMID: 27285122, PMCID: PMC5030143, DOI: 10.1002/cncr.30138.Peer-Reviewed Original ResearchConceptsMedian percent reductionImmune checkpoint therapyLesional responseStereotactic radiosurgeryCheckpoint therapyLesion volumeAnti-cytotoxic T-lymphocyte-associated protein 4Anti-programmed cell death protein 1T-lymphocyte-associated protein 4Anti-PD-1 therapyGreater median percent reductionsCell death protein 1Administration of immunotherapyWeeks of immunotherapyMelanoma brain metastasesDeath protein 1Type of immunotherapyWilcoxon rank sum testRank sum testNonconcurrent therapyBrain metastasesMelanoma patientsTreatment of cancerSingle institutionPercent reductionA contemporary dose selection algorithm for stereotactic radiosurgery in the treatment of brain metastases - An initial report.
Colaco RJ, Yu JB, Bond JS, Bindra RS, Contessa JN, Knisely JPS, Chiang VL. A contemporary dose selection algorithm for stereotactic radiosurgery in the treatment of brain metastases - An initial report. Journal Of Radiosurgery And SBRT 2016, 4: 43-52. PMID: 29296425, PMCID: PMC5658834.Peer-Reviewed Original ResearchWhole brain radiotherapyDistant intracranial recurrenceLocal recurrenceBrain metastasesRTOG 90Overall local recurrence ratePrevious whole-brain radiotherapyProspective phase 2 trialWhole-brain radiation therapyBrain radiation therapyLocal recurrence rateMonths overall survivalPhase 2 trialRisk regression analysisGuideline dosesBrain radiotherapyPrimary endpointIntracranial recurrenceOverall survivalFine-GrayPrescription dosesRecurrence rateRetrospective outcomesMedical recordsLesion volume
2011
A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases
Patel TR, McHugh BJ, Bi WL, Minja FJ, Knisely JP, Chiang VL. A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases. American Journal Of Neuroradiology 2011, 32: 1885-1892. PMID: 21920854, PMCID: PMC7966021, DOI: 10.3174/ajnr.a2668.Peer-Reviewed Original ResearchConceptsBrain metastasesMedian survivalMetastatic lesionsLesion sizeMost metastatic lesionsMR imaging changesPercent of lesionsInitial treatment volumeSystemic cancer therapyInitial lesion sizeIntracranial metastatic lesionsGK-SRSLesional responsePatient demographicsRadiographic responseInitial treatmentImaging changesMale sexTumor sizeLesion volumeStereotactic radiosurgeryTreatment dosePatientsLesionsRadiosurgery